WO2005004876A1 - Metodo para preparar una solucion acuosa de meloxicam y solucion acuosa resultante - Google Patents
Metodo para preparar una solucion acuosa de meloxicam y solucion acuosa resultante Download PDFInfo
- Publication number
- WO2005004876A1 WO2005004876A1 PCT/MX2003/000054 MX0300054W WO2005004876A1 WO 2005004876 A1 WO2005004876 A1 WO 2005004876A1 MX 0300054 W MX0300054 W MX 0300054W WO 2005004876 A1 WO2005004876 A1 WO 2005004876A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- meloxicam
- solution
- sodium
- ophthalmic solution
- aqueous ophthalmic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Definitions
- the invention relates to a method for solubilizing Meloxicam to prepare an ophthalmic solution that allows to offer greater efficacy, safety and performance in the treatment of various eye conditions.
- Meloxicam is a non-steroidal anti-inflammatory selective inhibitor of the enzyme cyclooxygenase-2 (COX-2) indicated for inflammation and post-surgical pain after cataract surgery and other surgical interventions such as refractive surgery, laser beam application, preoperative prophylaxis and postoperative cystoid macular edema in noninfectious inflammatory conditions in the anterior part of the eye, for example, allergic conjunctivitis.
- COX-2 cyclooxygenase-2
- Meloxicam is also indicated to inhibit transoperative myosis in intraocular surgeries, mainly in cataract surgery.
- the chemical name of Meloxicam is 4-hydroxy-2-methyl-7V- (5-methyl-2-thiazolyl) -2iY-1, 2-benzothiazine-3-carboxamide-1, 1-dioxide.
- the molecular weight is 351.4 and its empirical chemical formula is C 14 H 13 N 3 O 4 S 2 .
- Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the COX-2 selective inhibitor enolic acid group, which exerts anti-inflammatory, analgesic and antipyretic actions. It exerts intense anti-inflammatory activity in all experimental models of inflammation.
- NSAID non-steroidal anti-inflammatory drug
- Meloxicam as a cyclooxygenase-2 inhibitor, for the formulation of compounds for the treatment of ophthalmic diseases, such as retinitis, retinopathies, conjunctivitis, uveitis, ocular photophobia and lesions acute to eye tissue.
- This patent protects the formulation of Meloxicam in drops for topical administration to the eye, in which the active ingredients are dissolved or suspended in a suitable vehicle or carrier, especially an aqueous solvent for the active ingredients.
- a suitable vehicle or carrier especially an aqueous solvent for the active ingredients.
- this document does not specify those excipients with which Meloxicam would be dissolved or suspended.
- patent 6,136,839 specifies that the anti-inflammatory active ingredients, for the present case Meloxicam, are present in such formulations in a concentration that preferably ranges from 0.5% to 20%, especially 0.5% to 10% and particularly approximately 1.5% in formulation weight As will be seen below, the concentration ranges of Meloxicam in the aqueous solution of the present invention are outside those proposed in the aforementioned US patent.
- the main objective of the invention is to propose a method to solubilize Meloxicam with the purpose of preparing a new aqueous ophthalmic solution that solves the drawbacks of the currently available Meloxicam solutions.
- the aqueous ophthalmic solution is characterized in that it comprises: Meloxicam in a concentration range of 0.001% to 0.1%; a pH buffer system that can be boric acid, citric acid, sorbic acid, acetic acid, sodium borate, sodium monobasic phosphate, sodium dibasic phosphate, sodium citrate and sodium acetate, in a range of concentrations ranging from 0.001% to 5.0%; one or more agents that increase viscosity such as hydroxypropylmethylcellulose, carboxymethylcellulose, methylcellulose, polyvinyl alcohol, sodium hyaluronate, glycerin, formal glycerol, methylidinoglycerol and cyclodextrins, in concentrations ranging from 0.05% to 20.
- antioxidant agents such as disodium edetate, sodium metabisulphite, sodium bisulfite, acetylcysteine, sodium thiosulfate and thiourea in adequate concentrations to give the required effect.
- concentrations of conservatives are, for example, 0.005% to 0.02% benzalkonium chloride, 0.01% maximum benzetonium chloride, 0.005% to 0.02% thiomersal, 0.002% to 0.004% nitrate or phenylmercuric acetate, 0.2% maximum of parabens, 0.002% to 0.01% chlorhexidine gluconate and 0.15% to 0.5% chlorobutanol.
- the present invention relates to a method of solubilization of Meloxicam to prepare an aqueous ophthalmic solution whose clinical value is reflected in the safety, safety and treatment of the patient.
- Its pharmaceutical value lies in the handling of an easily accessible vehicle that not only allows the solubility of Meloxicam but also favors a greater tolerance of the patient to the treatment of various eye conditions.
- Phase 1 Solubilization of Meloxicam.
- Solution A 1- In a beaker, 1000 mL of ethyl alcohol and 1000 mL of methylidinoglycerol (methylidene) are placed, stirring is started at 500 m ⁇ 50 ⁇ m; 2- 15 g or 30 g of Meloxicam are added, alkalizing the solution with 4N sodium hydroxide, until Meloxicam is completely dissolved; and 3- add 500 mL of Polysorbate 80 and stir for approximately 5 minutes to homogenize the solution.
- Phase 2. (Preparation of a hauling solution.
- Solution B) l.- In a stainless steel plated tank, 70 liters of purified water are poured at 70 ° C ⁇ 2 ° C; 2.- stirring starts at 500 to 550 ⁇ m and remains constant throughout the preparation process; 3.- 7 Kg of Polyoxyl-40-Stearate are added maintaining the temperature for 10 minutes to allow it to dissolve; 4.- 100 g of Edetate disodium dihydrate are added and it is expected approximately 5 minutes for it to dissolve completely; 5.- 95 g of boric acid are added and it is expected approximately 5 minutes for it to dissolve completely; 6.- cold water recirculation begins in the tank jacket for 10 to 25 minutes until it reaches a temperature of 52 ° C ⁇ 2 ° C; 7.- 220 g of sorbic acid are added slowly maintaining the temperature of 52 ° C ⁇ 2 ° C for 25 to 35 minutes; 8.- the pH of the solution is measured and adjusted with sodium hydroxide to 7.15 ⁇ 0.15; 9.- cold water
- Phase 3 Preparation of an aqueous ophthalmic solution of Meloxicam.
- Solution C A) add solution A to solution B while the latter continues stirring for 500 to 550 ⁇ m; and B) complete the volume at 100 L with purified water and stirring is continued for 500 to 550 ⁇ m for approximately one more hour.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/564,271 US20070092539A1 (en) | 2003-07-10 | 2003-07-10 | Method of preparing an aqueous meloxicam solution and aqueous solution thus produced |
PCT/MX2003/000054 WO2005004876A1 (es) | 2003-07-10 | 2003-07-10 | Metodo para preparar una solucion acuosa de meloxicam y solucion acuosa resultante |
BRPI0318395-5A BR0318395A (pt) | 2003-07-10 | 2003-07-10 | método para preparar uma solução aquosa de meloxicam e a solução aquosa resultante |
EP08159211A EP1972340A3 (en) | 2003-07-10 | 2003-07-10 | Method of preparing an aqueous meloxicam solution and the resulting aqueous solution |
EP03817445A EP1649858A1 (en) | 2003-07-10 | 2003-07-10 | Method of preparing an aqueous meloxicam solution and aqueous solution thus produced |
AU2003243055A AU2003243055A1 (en) | 2003-07-10 | 2003-07-10 | Method of preparing an aqueous meloxicam solution and aqueous solution thus produced |
MXJL06000001A MXJL06000001A (es) | 2003-07-10 | 2006-01-10 | Metodo para preparar una solucion acuosa de meloxicam y solucion acuosa resultante. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/MX2003/000054 WO2005004876A1 (es) | 2003-07-10 | 2003-07-10 | Metodo para preparar una solucion acuosa de meloxicam y solucion acuosa resultante |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005004876A1 true WO2005004876A1 (es) | 2005-01-20 |
Family
ID=34056954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/MX2003/000054 WO2005004876A1 (es) | 2003-07-10 | 2003-07-10 | Metodo para preparar una solucion acuosa de meloxicam y solucion acuosa resultante |
Country Status (6)
Country | Link |
---|---|
US (1) | US20070092539A1 (es) |
EP (2) | EP1649858A1 (es) |
AU (1) | AU2003243055A1 (es) |
BR (1) | BR0318395A (es) |
MX (1) | MXJL06000001A (es) |
WO (1) | WO2005004876A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2197461B1 (en) | 2007-10-08 | 2018-02-21 | Aurinia Pharmaceuticals Inc. | Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors |
TR200809200A1 (tr) * | 2008-12-01 | 2009-12-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Meloksikam içeren farmasötik formülasyonlar |
US9017725B2 (en) * | 2009-06-09 | 2015-04-28 | Aurinia Pharmaceuticals Inc. | Topical drug delivery systems for ophthalmic use |
CN103110575B (zh) * | 2013-03-07 | 2014-11-05 | 宁夏康亚药业有限公司 | 一种美洛昔康滴眼液及其制备方法和应用 |
US20180168932A1 (en) * | 2016-12-20 | 2018-06-21 | Apotex Technologies Inc. | Meloxicam Dosage Forms |
US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
CN115494174B (zh) * | 2022-09-23 | 2024-03-29 | 南京瑞孚医药科技有限公司 | 一种高效液相色谱法检测美洛昔康中硫脲的方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2099272T3 (es) * | 1991-07-18 | 1997-05-16 | Europhta Lab | Composiciones oftalmicas a base de oxicam o de derivados de oxicam. |
US6284269B1 (en) * | 1997-08-27 | 2001-09-04 | Hexal Ag | Pharmaceutical compositions of meloxicam with improved solubility and bioavailability |
US6495603B1 (en) * | 1998-05-15 | 2002-12-17 | Wakamoto Pharmaceutical Co., Ltd. | Anti-inflammatory eye drop |
US20030055051A1 (en) * | 1999-11-24 | 2003-03-20 | Wakamoto Pharmaceutical Co., Ltd. | Ophthalmic aqueous pharmaceutical preparation |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136839A (en) | 1995-06-12 | 2000-10-24 | G. D. Searle & Co. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor |
MX9701946A (es) * | 1997-03-14 | 1998-04-30 | Arturo Jimenez Bayardo | Solucion oftalmica transportadora. |
DE10161077A1 (de) * | 2001-12-12 | 2003-06-18 | Boehringer Ingelheim Vetmed | Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion |
-
2003
- 2003-07-10 US US10/564,271 patent/US20070092539A1/en not_active Abandoned
- 2003-07-10 AU AU2003243055A patent/AU2003243055A1/en not_active Abandoned
- 2003-07-10 WO PCT/MX2003/000054 patent/WO2005004876A1/es active Application Filing
- 2003-07-10 EP EP03817445A patent/EP1649858A1/en not_active Withdrawn
- 2003-07-10 BR BRPI0318395-5A patent/BR0318395A/pt not_active IP Right Cessation
- 2003-07-10 EP EP08159211A patent/EP1972340A3/en not_active Withdrawn
-
2006
- 2006-01-10 MX MXJL06000001A patent/MXJL06000001A/es not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2099272T3 (es) * | 1991-07-18 | 1997-05-16 | Europhta Lab | Composiciones oftalmicas a base de oxicam o de derivados de oxicam. |
US6284269B1 (en) * | 1997-08-27 | 2001-09-04 | Hexal Ag | Pharmaceutical compositions of meloxicam with improved solubility and bioavailability |
US6495603B1 (en) * | 1998-05-15 | 2002-12-17 | Wakamoto Pharmaceutical Co., Ltd. | Anti-inflammatory eye drop |
US20030055051A1 (en) * | 1999-11-24 | 2003-03-20 | Wakamoto Pharmaceutical Co., Ltd. | Ophthalmic aqueous pharmaceutical preparation |
Also Published As
Publication number | Publication date |
---|---|
EP1972340A3 (en) | 2008-11-26 |
US20070092539A1 (en) | 2007-04-26 |
AU2003243055A1 (en) | 2005-01-28 |
BR0318395A (pt) | 2006-08-01 |
EP1972340A2 (en) | 2008-09-24 |
MXJL06000001A (es) | 2006-04-11 |
EP1649858A1 (en) | 2006-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2429443T3 (es) | Suministro transdérmico de sustancias beneficiosas efectuado mediante un entorno de fuerza iónica elevada | |
ES2620413T3 (es) | Formulaciones veterinarias antihelmínticas tópicas | |
JP2683676B2 (ja) | 局所投与用炎症性疾患治療剤 | |
US4545992A (en) | Pharmaceutical preparations | |
ES2320770T3 (es) | Metodo de preparacion de una solucion oftalmica de latanoprost y la solucion asi producida. | |
US20030069232A1 (en) | Topical treatment of ocular hypertension, glaucoma, ischemic retinopathy and age-related macular degeneration with ophthalmic formulation of dopamine antagonists | |
JP6117939B2 (ja) | ジクロフェナク組成物 | |
JPS63201133A (ja) | 混合ミセル溶液 | |
WO1999059634A1 (fr) | Gouttes oculaires anti-inflammatoires | |
CA2841358A1 (en) | Pharmaceutical compositions for rectal administration | |
JPH1160505A (ja) | 防腐組成物 | |
ES2221127T3 (es) | Uso de acitromicina en el tratamiento topico de infecciones oculares. | |
CA3001957C (en) | Ophthalmic solution of difluprednate | |
CZ2003966A3 (cs) | Farmaceutický prostředek obsahující sloučeninu modafinilu v roztoku | |
WO2005004876A1 (es) | Metodo para preparar una solucion acuosa de meloxicam y solucion acuosa resultante | |
JP2003206241A (ja) | 眼科用剤 | |
CA2391968A1 (en) | An improved pharmaceutical composition for treating male erectile dysfunction | |
WO2005044227A1 (en) | Topical pharmaceutical compositions | |
WO2004030665A1 (en) | Transparent gel composition, for the administration of diclofenac sodium through the skin | |
TWI586665B (zh) | 包含經取代γ內醯胺之眼用調配物及其使用方法 | |
JP2729859B2 (ja) | 可逆性熱ゲル化水性医薬組成物 | |
ES2352296T3 (es) | Emulsión de aceite en agua que comprende aine y haluros de amonio cuaternarios. | |
ES2361932T3 (es) | Inhibidor de angiogénesis que contiene un derivado de amina como ingrediente activo. | |
EP4076442A1 (en) | Pharmaceutical composition of cyclooxygenase - 2 inhibitors | |
ES2731754T3 (es) | Composición farmacéutica oftalmica que contiene un inhibidor de anhidrasa carbónica y método para la preparación de la misma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: JL/a/2006/000001 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003817445 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003817445 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0318395 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007092539 Country of ref document: US Ref document number: 10564271 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10564271 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |